Tumour Treating Fields for mesothelioma: controversy versus opportunity

Affiliations

¹ Leicester Cancer Research Centre, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK. Electronic address: df132@leicester.ac.uk.

Comment

Dean A Fennell. Lancet Oncol. 2019 Dec.

. 2019 Dec;20(12):1623-1625.

doi: 10.1016/S1470-2045(19)30642-4. Epub 2019 Oct 15.

¹ Leicester Cancer Research Centre, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK. Electronic address: df132@leicester.ac.uk.

No abstract available

Comment on

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F. Ceresoli GL, et al. Lancet Oncol. 2019 Dec;20(12):1702-1709. doi: 10.1016/S1470-2045(19)30532-7. Epub 2019 Oct 15. Lancet Oncol. 2019. PMID: 31628016 Clinical Trial.